Recent Press Releases

The Lancet: Scientists announce final trial results of the world's most advanced malaria vaccine

The first malaria vaccine candidate (RTS,S/AS01) to reach phase 3 clinical testing is partially effective against clinical disease in young African children up to 4 years after vaccination, according...

GSK response to MSF vaccines report

More children from the world's poorest countries are being vaccinated against more diseases than ever before. This is a good thing and has been made possible by unprecedented cooperation between...

Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results

BEIJING, April 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products inChina, today announced its unaudited financial results for the fourth...

Vical to Manufacture HIV Vaccines for Clinical Evaluation by Public-Private Partnership Initiative

Vical to receive $4 million under new contract with IPPOX Foundation, funded via a grant from the Bill & Melinda Gates Foundation, to supply plasmid DNA for HIV vaccine clinical trials Builds...

PaxVax Announces Global Expansion of Commercial Network for Its Typhoid Vaccine Vivotif

REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements...

Mymetics-Led Consortium Awarded €8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines

Mymetics virosome vaccine technology and HIV vaccine candidate to be used as basis to develop a scalable manufacturing process within 3.5 years Funding this project can represent a major...

Daiichi Sankyo and Terumo Announce Application in Japan for Manufacturing and Sales Approval of Intradermal Seasonal Influenza Vaccine

Tokyo, Japan, April 10, 2015 – Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and Terumo Corporation (hereafter, Terumo) today announced that Japan Vaccine Co., Ltd. (hereafter, Japan...

GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine

ATLANTA, GA--(Marketwired - Apr 14, 2015) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today...

Aduro Biotech Announces Pricing of Its Initial Public Offering

BERKELEY, Calif.-- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In...

Ebola vaccine trial begins in Sierra Leone

The Centers for Disease Control and Prevention (CDC), in partnership with the Sierra Leone College of Medicine and Allied Health Sciences (COMAHS) and the Sierra Leone Ministry of Health and...

Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone

KENILWORTH, N.J. & AMES, Iowa--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the...

Ichor Medical Systems Announces Strategic Collaboration with Johnson & Johnson Innovation to Develop and Commercialize Immunotherapies Delivered with TriGrid Electroporation Device for Chronic Hepatitis B

Published: Apr 13, 2015 8:00 a.m. ET SAN DIEGO, Apr 13, 2015 (BUSINESS WIRE) -- Ichor Medical Systems, Inc. (Ichor) announced today that it has entered into a product development collaboration and...

MEDI8897 Receives Fast Track Designation by the FDA for the Prevention of Respiratory Disease Caused by RSV in Infants

April 09, 2015 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.--(BUSINESS WIRE)--MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has received...

GeoVax HIV Vaccine Moves Forward

GeoVax Labs, a biotechnology company developing human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next...

Kathrin U. Jansen, Ph.D., to Lead Pfizer's Vaccine Research and Development Unit

Pfizer Inc. announced today that Kathrin U. Jansen, Ph.D., has been appointed Senior Vice President, Vaccine Research & Development, and will be responsible for leading all Pfizer vaccine...

Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for the Treatment of Advanced Prostate Cancer

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has...

VBI Vaccines Announces Research Collaboration With Sanofi Pasteur to Enhance Vaccine Stability

Sanofi Pasteur has chosen VBI's LPV™ technology to develop a more stable formulation of a key Sanofi Pasteur vaccine candidate. The collaboration will leverage VBI's LPV™...

GSK to establish global vaccines R&D centre in the US

New hub based in Rockville, MD expands GSK's global vaccines R&D footprint GSK announced today it is further strengthening and expanding its vaccines presence in the US by establishing a new...

GeoVax Provides Update on Its HIV Vaccine Program

New Clinical Trial Planned With HVTN and NIH Support; Concept Protocol Approved for HVTN 114 ATLANTA, GA--(Marketwired - Apr 1, 2015) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company...